Clinical Trial Detail

NCT ID NCT01723202
Title Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Comprehensive Cancer Network, Manisha Shah, Ohio State University Comprehensive Cancer Center
Indications

thyroid gland papillary carcinoma

thyroid gland follicular carcinoma

Therapies

Dabrafenib + Trametinib

Dabrafenib

Age Groups: adult

Additional content available in CKB BOOST